Cessatech

Anders comes with long-standing medical and commercial background in senior leadership positions in both large pharma and small biotech. His experience with planning and execution of global launches makes him an important addition to our Board at this pivotal moment for Cessatech.

Following today's appointment, the Board of Directors consists of Martin Olin (Chairman), Charlotte Videbæk, Flemming Steen Jensen, Rachel Curtis Gravesen and Anders Dyhr Dombernowsky-Toft.

"Cessatech is entering a new and exciting period with global commercializing of its lead candidate CT001 for acute pain management, and Anders' broad understanding of the international life sciences sector brings valuable experience to the Board of Directors," said Chairman of the Board of Directors Martin Olin. "I look forward to working with Anders and wish to thank Peter Birk for his valuable contributions to the company during the last years".